KOLs

GlobalData analyst highlights Leqselvi’s high-dose advantage and renewed market entry as key drivers for swift adoption, despite…

While prasinezumab missed its primary endpoint, time-to-event analyses suggest potential in delaying early Parkinson’s disease…